XGN
ANALYST COVERAGE10 analysts
BUY
+87.4%upside to target
L $8.00
Med $8.00consensus
H $10.00
Buy
10100%
10 Buy (100%)0 Hold (0%)0 Sell (0%)
Full report →
Key MetricsTTM
Market Cap$103.16M
Revenue TTM$68.38M
Net Income TTM-$20.17M
Free Cash Flow
Gross Margin58.3%
Operating Margin-20.6%
Net Margin-29.5%
Return on Equity-113.5%
Return on Assets-38.8%
Debt / Equity
Current Ratio3.47
EPS TTM
PRICE
Prev Close
3.83
Open
3.81
Day Range3.77 – 4.28
3.77
4.28
52W Range2.59 – 12.23
2.59
12.23
17% of range
VOLUME & SIZE
Avg Volume
378.3K
FUNDAMENTALS
P/E Ratio
-4.7x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.09
Market-like
TECHNICAL
RSI (14)
55
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20

XGN News

About

exagen diagnostics, inc. is a patient focused, discovery driven, clia-certified, cap-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of rheumatology and autoimmune diseases. committed to personalized medicine, our avise tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. for more information on our company, please visit www.exagen.com. for more information on avise testing services, please visit www.avisetest.com.

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Fortunato Rocca
Jeffrey G. BlackChief Financial Officer & Corporate Secretary
John AballiChief Executive Officer, President & Director
Tina JacobsenVice President of Investor Relations
Michael MahlerChief Scientific Officer
Prashanti ReddyChief Medical Officer
Tina S. NovaExecutive Chairman of the Board of Directors